rs112496830 - MAP3K4
Magnitude 2.2 · 2 studies on file
Reported associations
-
Metabolic GWAS of elite athletes reveals novel genetically-influenced metabolites associated with athletic performance - Unknown journal (n.d.) · Unknown authors · PubMed 31882771
ABSTRACT: Genetic research of elite athletic performance has been hindered by the complex phenotype and the relatively small effect size of the identified genetic variants. The aims of this study were to identify genetic predisposition to elite athletic performance by investigating genetically-influenced metabolites that discriminate elite athletes from non-elite athletes and to identify those associated with endurance sports. By conducting a genome wide association study with high-resolution metabolomics profiling in 490 elite athletes, common variant metabolic quantitative trait loci (mQTLs) were identified and compared with previously identified mQTLs in non-elite athletes. Among the identified mQTLs, those associated with endurance metabolites were determined. Two novel genetic loci in
-
Genetics of 35 blood and urine biomarkers in the UK Biobank - Unknown journal (n.d.) · Unknown authors · PubMed 33462484
ABSTRACT: Clinical laboratory tests are a critical component of the continuum of care. We evaluate the genetic basis of 35 blood and urine laboratory measurements in the UK Biobank (n=363,228 individuals). We identify 1,857 loci associated with at least one trait, containing 3,374 fine-mapped associations, and additional sets of large-effect (> 0.1 sd) protein-altering, HLA, and copy-number variant associations. Through Mendelian Randomization analysis, we discover 51 causal relationships, including previously known agonistic effects of urate on gout and cystatin C on stroke. Finally, we develop polygenic risk scores for each biomarker and built 'multi-PRS' models for diseases using 35 PRSs simultaneously, which improved chronic kidney disease, type 2 diabetes, gout, and alcoholic cirr
Auto-generated from study metadata. AI-synthesised commentary is added when this entry is regenerated through content-service's LLM mode.
Lifestyle context
Concrete actions anchored to the cited research. We do not prescribe, we describe.
Discuss with your doctor
-
Lp(a) treatment options and cardiovascular risk management Moderate
Elevated Lp(a) may warrant specific pharmacological or intervention strategies
- GWAS_CATALOG:33462484
Lifestyle
-
cardiovascular risk reduction program Moderate
Elevated Lp(a) requires aggressive management of modifiable cardiovascular risk factors
regular aerobic exercise, heart-healthy diet, maintain healthy weight, manage stress
- GWAS_CATALOG:33462484
Screening
-
lipoprotein (a) and cardiovascular risk assessment Moderate
Elevated Lp(a) increases risk of coronary artery disease and stroke
baseline cardiovascular assessment with annual lipid panel and Lp(a) measurement
- GWAS_CATALOG:33462484